Boy, eight, urges company to lower price of cystic fibrosis drug


An eight-year-old boy with cystic fibrosis has urged a pharmaceutical company to lower the price of a drug so it can be made available on the NHS. Orkambi received its European licence exactly 1,000 days ago, but the National Institute of Care and Excellence has not recommended it for use on grounds of cost-effectiveness.



from Biotech News